Analysts at Morgan Stanley initiated coverage on shares of Myriad Genetics MYGN with a Underperform rating.
The target price for Myriad Genetics is set to $25.
Myriad Genetics shares have gained 29.61% over the past 52 weeks, while the S&P 500 index has surged 14.68% in the same period.
Myriad Genetics' shares fell 1.98% to $34.20 in pre-market trading.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in